Skip to content
sellModerate

Dinesh Ph D Patel V sold $2.9M of PTGX

President and CEO at Protagonist Therapeutics, Inc. 52,444 shares at an average of $54.92, traded Jul 21, 2025, filed Jul 23, 2025.

Warning score
50
Value
$2.9M
52,444 shares
Holdings after
531,018
-9% from before
From 52-week low
+57%
low $35.09, close $55.22
From 52-week high
-8%
high $59.76, as of Jul 21, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $2.9M at market
    +25
  • Share of holdings sold
    Sold 9.0% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +6.1%, 3m +35.6%, 6m +54.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTGXOct 9, 2026 · close 143.73
Since filing Jul 23, 2025: +165.2%SPY +24.4% · excess +140.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-070104, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 21, 2025AGrant or award
Common Stock
+25,000$0.00$0583,462Jul 23, 2025
Jul 21, 2025SOpen-market sale
Common Stock
-12,859$54.86$705k570,603Jul 23, 2025
Jul 22, 2025SOpen-market sale
Common Stock
-22,065$55.05$1.2M548,538Jul 23, 2025
Jul 23, 2025SOpen-market sale
Common Stock
-17,520$54.79$960k531,018Jul 23, 2025

Related signals

Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
22Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$8.3M
58,629 shares
-50%
20Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$18M
125,000 shares
-22%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$1.1M
9,000 shares
-53%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$969k
9,000 shares
-53%
24Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$897k
9,000 shares
-53%
28Weak
PTGXsell 210b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$7.5M
75,000 shares
-13%
48Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$7.5M
75,000 shares
-13%
53Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Bryan Giraudo
director
$5.9M
59,130 shares
-93%
34Weak
PTGXsell
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$185k
1,750 shares
-3%
57Moderate
PTGXsell 4
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$2.6M
24,765 shares
-29%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Dinesh Ph D Patel V sold $2.9M of PTGX | InsiderTell